(PHAT) Phathom Pharmaceuticals - Ratings and Ratios

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal disorders. The company holds exclusive rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB), a drug candidate designed to inhibit acid secretion in the stomach. Its lead product, vonoprazan, is a novel P-CAB being developed for the treatment of erosive gastroesophageal reflux disease (EGERD) and Helicobacter pylori (H. pylori) infection when combined with antibiotics. Vonoprazans mechanism of action provides faster onset and longer duration of acid suppression compared to traditional proton pump inhibitors (PPIs), addressing limitations of existing therapies. Established in 2018, Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey.

Based on the provided and , here is a 3-month forecast: - Technical Outlook: The stock is currently trading at $5.76, below its 20-day SMA of $5.74 but significantly below its 50-day SMA of $6.71 and 200-day SMA of $11.43. This indicates a bearish trend. The ATR of 0.46 suggests moderate volatility. If the stock breaks below $5.50, it may test lower support levels. Conversely, a move above $6.20 could signal a reversal. - Fundamental Outlook: With a market cap of $387.70M and a P/B ratio of 25.37, the stock is richly valued relative to book value. The P/S ratio of 14.76 indicates a premium for revenue growth potential. The RoE of 181.41% reflects strong profitability, though the lack of forward P/E suggests uncertainty in earnings estimates. Over the next three months, expect volatility driven by clinical trial updates and broader market conditions.